153 related articles for article (PubMed ID: 29386312)
21. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab.
Nakaya A; Kurata T; Yoshioka H; Takeyasu Y; Niki M; Kibata K; Satsutani N; Ogata M; Miyara T; Nomura S
Int J Clin Oncol; 2018 Aug; 23(4):634-640. PubMed ID: 29442281
[TBL] [Abstract][Full Text] [Related]
22. Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153.
Waterhouse D; Horn L; Reynolds C; Spigel D; Chandler J; Mekhail T; Mohamed M; Creelan B; Blankstein KB; Nikolinakos P; McCleod MJ; Li A; Oukessou A; Agrawal S; Aanur N
Cancer Chemother Pharmacol; 2018 Apr; 81(4):679-686. PubMed ID: 29442139
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review.
Guidi A; Codecà C; Ferrari D
Med Oncol; 2018 Feb; 35(3):37. PubMed ID: 29441454
[TBL] [Abstract][Full Text] [Related]
24. Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study.
Petrylak DP; Powles T; Bellmunt J; Braiteh F; Loriot Y; Morales-Barrera R; Burris HA; Kim JW; Ding B; Kaiser C; Fassò M; O'Hear C; Vogelzang NJ
JAMA Oncol; 2018 Apr; 4(4):537-544. PubMed ID: 29423515
[TBL] [Abstract][Full Text] [Related]
25. The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis.
Huang G; Sun X; Liu D; Zhang Y; Zhang B; Xiao G; Li X; Gao X; Hu C; Wang M; Ren H; Qin S
Oncotarget; 2018 Jan; 9(3):4239-4248. PubMed ID: 29423118
[TBL] [Abstract][Full Text] [Related]
26. Germline polymorphism of interferon-lambda3 is clinically associated with progression of renal cell carcinoma.
Nukui A; Yanai Y; Tsuzuki T; Abe H; Arai K; Yoshida KI; Kamai T
Oncotarget; 2018 Jan; 9(3):4188-4199. PubMed ID: 29423114
[TBL] [Abstract][Full Text] [Related]
27. Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells.
Lai Q; Wang H; Li A; Xu Y; Tang L; Chen Q; Zhang C; Gao Y; Song J; Du Z
Oncogene; 2018 Apr; 37(17):2302-2312. PubMed ID: 29422611
[TBL] [Abstract][Full Text] [Related]
28. Case of advanced pulmonary squamous cell carcinoma cured by resection through preoperative induction of immune checkpoint inhibitor.
Kawai H; Saito Y; Demura R; Odaka H; Takahashi S; Takahashi K; Kurokawa H; Enomoto K
Thorac Cancer; 2018 Apr; 9(4):495-497. PubMed ID: 29418077
[TBL] [Abstract][Full Text] [Related]
29. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.
Faiena I; Cummings AL; Crosetti AM; Pantuck AJ; Chamie K; Drakaki A
Drug Des Devel Ther; 2018; 12():209-215. PubMed ID: 29416316
[TBL] [Abstract][Full Text] [Related]
30. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
[TBL] [Abstract][Full Text] [Related]
31. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.
Kalemkerian GP; Narula N; Kennedy EB; Biermann WA; Donington J; Leighl NB; Lew M; Pantelas J; Ramalingam SS; Reck M; Saqi A; Simoff M; Singh N; Sundaram B
J Clin Oncol; 2018 Mar; 36(9):911-919. PubMed ID: 29401004
[TBL] [Abstract][Full Text] [Related]
32. Duration of Anti-Programmed Death-1 Therapy in Advanced Melanoma: How Much of a Good Thing Is Enough?
Khushalani NI
J Clin Oncol; 2018 Jun; 36(17):1649-1653. PubMed ID: 29389234
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.
Song Z; Cheng G; Xu C; Wang W; Shao Y; Zhang Y
Lung Cancer; 2018 Apr; 118():57-61. PubMed ID: 29572003
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non-Small Cell Lung Cancer: Brief Report.
Owada-Ozaki Y; Muto S; Takagi H; Inoue T; Watanabe Y; Fukuhara M; Yamaura T; Okabe N; Matsumura Y; Hasegawa T; Ohsugi J; Hoshino M; Shio Y; Nanamiya H; Imai JI; Isogai T; Watanabe S; Suzuki H
J Thorac Oncol; 2018 Aug; 13(8):1217-1221. PubMed ID: 29654927
[TBL] [Abstract][Full Text] [Related]
35. The Significant Antitumor Activity of Nivolumab in Lung Adenocarcinoma with Choriocarcinomatous Features.
Ochi M; Miyamoto S; Terada Y; Furuhata Y; Awano N; Izumo T; Ikushima S; Bae Y; Kumasaka T; Kunito H
Intern Med; 2018 Jun; 57(12):1773-1777. PubMed ID: 29434118
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Toxicity of Fifth-line Nivolumab in a 15-Year-Old Girl With Metastatic Juvenile Renal Cell Carcinoma.
Akbaraly T; Saguintaah M; Topart D; Sirvent N
J Pediatr Hematol Oncol; 2018 Apr; 40(3):251-252. PubMed ID: 29420369
[No Abstract] [Full Text] [Related]
37. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.
Vanderwalde A; Spetzler D; Xiao N; Gatalica Z; Marshall J
Cancer Med; 2018 Mar; 7(3):746-756. PubMed ID: 29436178
[TBL] [Abstract][Full Text] [Related]
38. Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing.
Suh JH; Schrock AB; Johnson A; Lipson D; Gay LM; Ramkissoon S; Vergilio JA; Elvin JA; Shakir A; Ruehlman P; Reckamp KL; Ou SI; Ross JS; Stephens PJ; Miller VA; Ali SM
Oncologist; 2018 Jul; 23(7):776-781. PubMed ID: 29540602
[TBL] [Abstract][Full Text] [Related]
39. Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.
Fabrizio DA; George TJ; Dunne RF; Frampton G; Sun J; Gowen K; Kennedy M; Greenbowe J; Schrock AB; Hezel AF; Ross JS; Stephens PJ; Ali SM; Miller VA; Fakih M; Klempner SJ
J Gastrointest Oncol; 2018 Aug; 9(4):610-617. PubMed ID: 30151257
[TBL] [Abstract][Full Text] [Related]
40. Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
Millis SZ; Jardim DL; Albacker L; Ross JS; Miller VA; Ali SM; Kurzrock R
Cancer; 2019 Apr; 125(7):1185-1199. PubMed ID: 30582752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]